Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Risk stratification for central conventional chondrosarcoma of bone: A novel system predicting risk of metastasis and death in the Cancer Registry of Norway cohort.

Thorkildsen J, Taksdal I, Bjerkehagen B, Norum OJ, Myklebust TA, Zaikova O.

J Surg Oncol. 2020 Mar 5. doi: 10.1002/jso.25883. [Epub ahead of print]

PMID:
32141094
2.

"Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial."

Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ.

Int J Radiat Oncol Biol Phys. 2020 Feb 26. pii: S0360-3016(20)30253-4. doi: 10.1016/j.ijrobp.2020.02.027. [Epub ahead of print] No abstract available.

PMID:
32112877
3.

Unmet rehabilitation needs in 86% of Norwegian paediatric embryonal brain tumour survivors.

Stensvold E, Stadskleiv K, Myklebust TÅ, Wesenberg F, Helseth E, Bechensteen AG, Brandal P.

Acta Paediatr. 2020 Jan 24. doi: 10.1111/apa.15188. [Epub ahead of print]

PMID:
31977119
4.

Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.

Huynh-Le MP, Myklebust TÅ, Feng CH, Karunamuni R, Johannesen TB, Dale AM, Andreassen OA, Seibert TM.

Cancer. 2020 Apr 15;126(8):1691-1699. doi: 10.1002/cncr.32702. Epub 2020 Jan 3.

PMID:
31899813
5.

Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study.

Kvammen Ø, Myklebust TÅ, Solberg A, Møller B, Klepp OH, Fosså SD, Tandstad T.

PLoS One. 2019 Dec 18;14(12):e0225942. doi: 10.1371/journal.pone.0225942. eCollection 2019.

6.

Transanal total mesorectal excision for rectal cancer has been suspended in Norway.

Wasmuth HH, Faerden AE, Myklebust TÅ, Pfeffer F, Norderval S, Riis R, Olsen OC, Lambrecht JR, Kørner H, Larsen SG; Norwegian TaTME Collaborative Group, on behalf of the Norwegian Colorectal Cancer Group, Forsmo HM, Baekkelund O, Lavik S, Knapp JC, Sjo O, Rashid G.

Br J Surg. 2020 Jan;107(1):121-130. doi: 10.1002/bjs.11459. Epub 2019 Dec 5.

PMID:
31802481
7.

Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial.

Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ.

Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):706-714. doi: 10.1016/j.ijrobp.2019.11.027. Epub 2019 Nov 28.

PMID:
31786279
8.

Can We Optimize Antibiotic Use in Norwegian Neonates? A Prospective Comparison Between a University Hospital and a District Hospital.

Thaulow CM, Berild D, Blix HS, Brigtsen AK, Myklebust TÅ, Eriksen BH.

Front Pediatr. 2019 Oct 24;7:440. doi: 10.3389/fped.2019.00440. eCollection 2019.

9.

An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.

Enerly E, Flingtorp R, Christiansen IK, Campbell S, Hansen M, Myklebust TÅ, Weiderpass E, Nygård M.

PLoS One. 2019 Oct 10;14(10):e0223612. doi: 10.1371/journal.pone.0223612. eCollection 2019. Erratum in: PLoS One. 2019 Dec 12;14(12):e0226706.

10.

Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era.

Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, Tandstad T, Wilsgaard T, Fosså SD, Haugnes HS.

Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32704. [Epub ahead of print]

PMID:
31597192
11.

Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patients.

Kvåle R, Myklebust TÅ, Fosså SD, Aas K, Ekanger C, Helle SI, Honoré A, Møller B.

Prostate. 2019 Dec;79(16):1852-1860. doi: 10.1002/pros.23911. Epub 2019 Sep 30.

PMID:
31566779
12.

Mitigating risk in Norwegian psychiatric care: Identifying triggers of adverse events through Global Trigger Tool for psychiatric care.

Okkenhaug A, Tritter JQ, Myklebust TÅ, Deilkås ET, Meirik K, Landstad BJ.

Int J Risk Saf Med. 2019;30(4):203-216. doi: 10.3233/JRS-190064.

PMID:
31561389
13.

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.

Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TÅ, Tervonen H, Thursfield V, Ransom D, Shack L, Woods RR, Turner D, Leonfellner S, Ryan S, Saint-Jacques N, De P, McClure C, Ramanakumar AV, Stuart-Panko H, Engholm G, Walsh PM, Jackson C, Vernon S, Morgan E, Gavin A, Morrison DS, Huws DW, Porter G, Butler J, Bryant H, Currow DC, Hiom S, Parkin DM, Sasieni P, Lambert PC, Møller B, Soerjomataram I, Bray F.

Lancet Oncol. 2019 Nov;20(11):1493-1505. doi: 10.1016/S1470-2045(19)30456-5. Epub 2019 Sep 11.

14.

Lifestyle predictors of successful aging: A 20-year prospective HUNT study.

Bosnes I, Nordahl HM, Stordal E, Bosnes O, Myklebust TÅ, Almkvist O.

PLoS One. 2019 Jul 11;14(7):e0219200. doi: 10.1371/journal.pone.0219200. eCollection 2019.

15.

Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival.

Stensvold E, Myklebust TÅ, Cappelen J, Due-Tønnessen BJ, Due-Tønnessen P, Kepka A, Johannesen TB, Krossnes B, Lundar T, Maric S, Miletic H, Moholdt V, Myrmel KS, Nordberg T, Rydland J, Stokland T, Solem K, Solheim O, Torsvik I, Wikran GC, Zeller B, Wesenberg F, Bechensteen AG, Brandal P.

Pediatr Blood Cancer. 2019 Oct;66(10):e27910. doi: 10.1002/pbc.27910. Epub 2019 Jul 1.

PMID:
31264356
16.
17.

Influence of Mammography Volume on Radiologists' Performance: Results from BreastScreen Norway.

Hoff SR, Myklebust TÅ, Lee CI, Hofvind S.

Radiology. 2019 Aug;292(2):289-296. doi: 10.1148/radiol.2019182684. Epub 2019 May 28.

PMID:
31135295
18.

Second cancers in radically treated Norwegian prostate cancer patients.

Aksnessæther BY, Lund JÅ, Myklebust TÅ, Klepp OH, Skovlund E, Roth Hoff S, Solberg A.

Acta Oncol. 2019 Jun;58(6):838-844. doi: 10.1080/0284186X.2019.1581377. Epub 2019 Mar 25.

PMID:
30905229
19.

Potential for More Rational Use of Antibiotics in Hospitalized Children in a Country With Low Resistance: Data From eight Point Prevalence Surveys.

Thaulow CM, Berild D, Eriksen BH, Myklebust TÅ, Blix HS.

Pediatr Infect Dis J. 2019 Apr;38(4):384-389. doi: 10.1097/INF.0000000000002106.

PMID:
30882728
20.

Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.

Orumaa M, Leinonen MK, Campbell S, Møller B, Myklebust TÅ, Nygård M.

Int J Cancer. 2019 Nov 15;145(10):2629-2638. doi: 10.1002/ijc.32195. Epub 2019 Mar 4.

21.

Clinical outcome after surgery for lumbar spinal stenosis in patients with insignificant lower extremity pain. A prospective cohort study from the Norwegian registry for spine surgery.

Hermansen E, Myklebust TÅ, Austevoll IM, Rekeland F, Solberg T, Storheim K, Grundnes O, Aaen J, Brox JI, Hellum C, Indrekvam K.

BMC Musculoskelet Disord. 2019 Jan 22;20(1):36. doi: 10.1186/s12891-019-2407-5.

22.

Is time from diagnosis to radical prostatectomy associated with oncological outcomes?

Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V.

World J Urol. 2019 Aug;37(8):1571-1580. doi: 10.1007/s00345-018-2570-6. Epub 2018 Nov 27.

PMID:
30483947
23.

Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV.

Knudsen-Baas KM, Johannesen TB, Myklebust TÅ, Aarseth JH, Owe JF, Gilhus NE, Storstein AM.

J Neurooncol. 2018 Dec;140(3):739-748. doi: 10.1007/s11060-018-03007-9. Epub 2018 Nov 23.

PMID:
30471051
24.

MGMT Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas.

Johannessen LE, Brandal P, Myklebust TÅ, Heim S, Micci F, Panagopoulos I.

Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):437-446. doi: 10.21873/cgp.20102.

25.
26.

Factors influencing access to palliative radiotherapy: a Norwegian population-based study.

Åsli LM, Myklebust TÅ, Kvaløy SO, Jetne V, Møller B, Levernes SG, Johannesen TB.

Acta Oncol. 2018 Sep;57(9):1250-1258. doi: 10.1080/0284186X.2018.1468087. Epub 2018 Apr 28.

PMID:
29706109
27.

Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?

Aksnessæther BY, Solberg A, Klepp OH, Myklebust TÅ, Skovlund E, Hoff SR, Vatten LJ, Lund JÅ.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):211-216. doi: 10.1016/j.ijrobp.2018.01.096. Epub 2018 Feb 5.

PMID:
29534900
28.

Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.

Sriskandarajah S, Bostad L, Myklebust TÅ, Møller B, Skrede S, Bjørneklett R.

Int J Nephrol. 2017;2017:6013038. doi: 10.1155/2017/6013038. Epub 2017 Dec 18.

29.

Stage-specific incidence and survival of breast cancer in Norway: The implications of changes in coding and classification practice.

Larsen IK, Myklebust TÅ, Johannesen TB, Møller B, Hofvind S.

Breast. 2018 Apr;38:107-113. doi: 10.1016/j.breast.2017.12.001. Epub 2018 Jan 5.

PMID:
29306771
30.

Reply to M. Løberg et al.

Bains SJ, Mahic M, Myklebust TÅ, Småstuen MC, Yaqub S, Dørum LM, Bjørnbeth BA, Møller B, Brudvik KW, Taskén K.

J Clin Oncol. 2017 Feb 10;35(5):569-571. doi: 10.1200/JCO.2016.70.8263. Epub 2016 Nov 14. No abstract available.

PMID:
29236616
31.

Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.

Boyar Cetinkaya R, Aagnes B, Myklebust TÅ, Thiis-Evensen E.

Int J Cancer. 2018 Mar 15;142(6):1139-1147. doi: 10.1002/ijc.31137. Epub 2017 Nov 15.

32.

Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway.

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD.

Urology. 2017 Dec;110:140-147. doi: 10.1016/j.urology.2017.07.048. Epub 2017 Aug 18.

PMID:
28823634
33.

Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.

Kvåle R, Myklebust TÅ, Engholm G, Heinävaara S, Wist E, Møller B.

Int J Cancer. 2017 Dec 1;141(11):2228-2242. doi: 10.1002/ijc.30924. Epub 2017 Aug 26.

34.

How Many Deaths from Colorectal Cancer Can Be Prevented by 2030? A Scenario-Based Quantification of Risk Factor Modification, Screening, and Treatment in Norway.

Skyrud KD, Myklebust TÅ, Bray F, Eriksen MT, de Lange T, Larsen IK, Møller B.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1420-1426. doi: 10.1158/1055-9965.EPI-17-0265. Epub 2017 Jun 16.

35.

Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study.

Åsli LM, Johannesen TB, Myklebust TÅ, Møller B, Eriksen MT, Guren MG.

Radiother Oncol. 2017 Jun;123(3):446-453. doi: 10.1016/j.radonc.2017.04.012. Epub 2017 May 5.

PMID:
28483302
36.

Pre- and post-prostatectomy variables associated with pelvic post-operative radiotherapy in prostate cancer patients: a national registry-based study.

Vatne K, Stensvold A, Myklebust TÅ, Møller B, Svindland A, Kvåle R, Fosså SD.

Acta Oncol. 2017 Oct;56(10):1295-1301. doi: 10.1080/0284186X.2017.1314006. Epub 2017 Apr 19.

PMID:
28422584
37.

Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis spanning 40 years of treatment.

Stensvold E, Krossnes BK, Lundar T, Due-Tønnessen BJ, Frič R, Due-Tønnessen P, Bechensteen AG, Myklebust TÅ, Johannesen TB, Brandal P.

Acta Oncol. 2017 May;56(5):698-705. doi: 10.1080/0284186X.2017.1301679. Epub 2017 Mar 21.

PMID:
28325133
38.

Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study.

Reigstad MM, Storeng R, Myklebust TÅ, Oldereid NB, Omland AK, Robsahm TE, Brinton LA, Vangen S, Furu K, Larsen IK.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):953-962. doi: 10.1158/1055-9965.EPI-16-0809. Epub 2017 Jan 20.

39.

Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway.

Andreassen BK, Myklebust TÅ, Haug ES.

Scand J Urol. 2017 Feb;51(1):38-43. doi: 10.1080/21681805.2016.1271354. Epub 2017 Jan 13.

PMID:
28084860
40.

Two countries - Two treatment strategies for rectal cancer.

Glimelius B, Myklebust TÅ, Lundqvist K, Wibe A, Guren MG.

Radiother Oncol. 2016 Dec;121(3):357-363. doi: 10.1016/j.radonc.2016.11.010. Epub 2016 Nov 23.

PMID:
27887734
41.

A population-based study on incidence rates, Lauren distribution, stage distribution, treatment, and long-term outcomes for gastric adenocarcinoma in Central Norway 2001-2011.

Bringeland EA, Wasmuth HH, Mjønes P, Myklebust TÅ, Grønbech JE.

Acta Oncol. 2017 Jan;56(1):39-45. doi: 10.1080/0284186X.2016.1227086. Epub 2016 Oct 6.

PMID:
27710159
42.

National Early Rectal Cancer Treatment Revisited.

Stornes T, Wibe A, Nesbakken A, Myklebust TÅ, Endreseth BH.

Dis Colon Rectum. 2016 Jul;59(7):623-9. doi: 10.1097/DCR.0000000000000591.

PMID:
27270514
43.

Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study.

Bains SJ, Mahic M, Myklebust TÅ, Småstuen MC, Yaqub S, Dørum LM, Bjørnbeth BA, Møller B, Brudvik KW, Taskén K.

J Clin Oncol. 2016 Jul 20;34(21):2501-8. doi: 10.1200/JCO.2015.65.3519. Epub 2016 May 31.

PMID:
27247217
44.

An empirical comparison of methods for predicting net survival.

Myklebust TÅ, Aagnes B, Møller B.

Cancer Epidemiol. 2016 Jun;42:133-9. doi: 10.1016/j.canep.2016.04.006. Epub 2016 Apr 23.

PMID:
27111414
45.

Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26).

Fosså SD, Storås AH, Steinsvik EA, Myklebust TA, Eri LM, Loge JH, Dahl AA.

Scand J Urol. 2016 Aug;50(4):280-5. doi: 10.3109/21681805.2016.1163617. Epub 2016 Apr 6.

PMID:
27049891
46.

Risk of Cancer in Children Conceived by Assisted Reproductive Technology.

Reigstad MM, Larsen IK, Myklebust TÅ, Robsahm TE, Oldereid NB, Brinton LA, Storeng R.

Pediatrics. 2016 Mar;137(3):e20152061. doi: 10.1542/peds.2015-2061. Epub 2016 Feb 4.

47.

Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor.

Kvammen Ø, Myklebust TÅ, Solberg A, Møller B, Klepp OH, Fosså SD, Tandstad T.

Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):773-9. doi: 10.1158/1055-9965.EPI-15-1153. Epub 2016 Feb 11.

48.

The Nordic Health Registries: an important part of modern medical research.

Reigstad MM, Larsen IK, Myklebust TÅ, Robsahm TE, Oldereid NB, Omland AK, Vangen S, Storeng R.

Hum Reprod. 2016 Jan;31(1):216-7. doi: 10.1093/humrep/dev276. Epub 2015 Oct 29. No abstract available.

PMID:
26516204
49.

Cancer risk among parous women following assisted reproductive technology.

Reigstad MM, Larsen IK, Myklebust TÅ, Robsahm TE, Oldereid NB, Omland AK, Vangen S, Brinton LA, Storeng R.

Hum Reprod. 2015 Aug;30(8):1952-63. doi: 10.1093/humrep/dev124. Epub 2015 Jun 24.

50.

Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010.

Guren MG, Kørner H, Pfeffer F, Myklebust TÅ, Eriksen MT, Edna TH, Larsen SG, Knudsen KO, Nesbakken A, Wasmuth HH, Vonen B, Hofsli E, Færden AE, Brændengen M, Dahl O, Steigen SE, Johansen MJ, Lindsetmo RO, Drolsum A, Tollåli G, Dørum LM, Møller B, Wibe A.

Acta Oncol. 2015 Nov;54(10):1714-22. doi: 10.3109/0284186X.2015.1034876. Epub 2015 Apr 30.

PMID:
25924970

Supplemental Content

Loading ...
Support Center